Prakash S. Masand

Duke University — United States

Medicine · Health Sciences

50h-index8.1kcitations286works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Treatment of Major Depression(96), Schizophrenia research and treatment(80), Bipolar Disorder and Treatment(58), Electroconvulsive Therapy Studies(31), Tryptophan and brain disorders(29)

Publications286 total

Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease: Clinical Perspectives
Clinical Psychopharmacology and Neuroscience·2025Open Access
Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder
Journal of Medical Economics·2025Open Access
Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)
Psychopharmacology Bulletin·2025· 14 cited
Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder
ClinicoEconomics and Outcomes Research·2025Open Access
Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder
Journal of Affective Disorders·2025Open Access
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder
Journal of Affective Disorders·2025· 3 citedOpen Access
Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder
The Journal of Clinical Psychiatry·2025· 4 cited
ASSESSING MYOCARDIAL ISCHEMIA IN REPAIRED AND UNREPAIRED AAOCA: MEDIUM TO LONG TERM OUTCOMES IN A PEDIATRIC COHORT
Journal of the American College of Cardiology·2025Open Access
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States
Journal of Medical Economics·2025· 1 citedOpen Access
Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder
Journal of Medical Economics·2025· 3 citedOpen Access
Effect of Adjunctive Cariprazine on Symptoms of Anhedonia in Patients with Major Depressive Disorder
CNS Spectrums·2024· 1 citedOpen Access
Wall motion assessment by feature tracking in pediatric patients with coronary anomalies undergoing dobutamine stress CMR
Frontiers in Cardiovascular Medicine·2024· 1 citedOpen Access
The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
Clinical Psychopharmacology and Neuroscience·2024· 1 citedOpen Access
Estimating Changes in Weight and Metabolic Parameters Before and After Treatment With Cariprazine: A Retrospective Study of Electronic Health Records
Clinical Therapeutics·2023· 7 citedOpen Access
Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
Clinical Psychopharmacology and Neuroscience·2023· 2 citedOpen Access
Categorical Improvement in Depressive Symptom Severity: Results From a Randomized Controlled Trial of Cariprazine for Adjunctive Treatment of MDD
CNS Spectrums·2023· 1 citedOpen Access
Dermatofibrosarcoma protuberans case report: Aggressive tumor in a preadolescent child
Journal of Pediatric Surgery Case Reports·2023· 1 citedOpen Access
ASSESSING MYOCARDIAL ISCHEMIA AFTER REPAIR OF AAOCA: MEDIUM TO LONG TERM OUTCOMES
Journal of the American College of Cardiology·2023Open Access
Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
Clinical Psychopharmacology and Neuroscience·2023· 18 citedOpen Access
Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
Psychiatry Investigation·2022· 1 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Ashwin A. Patkar(22), Chi‐Un Pae(18), Hans‐Jürgen Möller(13), Sanjay Gupta(6), Sheng‐Min Wang(6), David M. Marks(6), Soo-Jung Lee(5), Paolo Mannelli(5), Kathleen Peindl(5), Alessandro Serretti(4), Soo-Jung Lee(3), Thomas L. Schwartz(3), Sanjay Gupta(2), John M. Kane(2), David S. Kaplan(2), S. B. Gupta(2), Bradford Frank(2), Stan Krulewicz(2), Anil Sipahimalani(2), Patricia Pickett(2)